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Abstract
Purpose Intracranial carotid artery occlusion represents an underinvestigated cause of acute ischemic stroke as well as an
indication for mechanical thrombectomy. We investigated baseline and procedural characteristics, outcomes and predictors
of outcome in patients with acute ischemic stroke secondary to intracranial carotid artery occlusion.
Methods A retrospective analysis of the Italian Registry of Endovascular Treatment in Acute Stroke was performed.
Patients with intracranial carotid artery occlusion (infraclinoid and supraclinoid) with or without cervical artery occlusion
but with patent intracranial arteries were included. The 3-month functional independence, mortality, successful reperfusion
and symptomatic intracranial hemorrhage were evaluated.
Results Intracranial carotid artery occlusion with patent intracranial arteries was diagnosed in 387 out of 4940 (7.8%)
patients. The median age was 74 years and median baseline National Institute of Health Stroke Scale (NIHSS) was 18.
Functional independence was achieved in 130 (34%) patients, successful reperfusion in 289 (75%) and symptomatic
intracranial hemorrhage in 33 (9%), whereas mortality occurred in 111 (29%) patients. In univariate analysis functional
independence was associated with lower age, lower NIHSS at presentation, higher rate of successful reperfusion and lower
rate of symptomatic intracranial hemorrhage. Multivariable regression analysis found age (odds ratio, OR:1.03; P= 0.006),
NIHSS at presentation (OR: 1.07; P< 0.001), diabetes (OR: 2.60; P= 0.002), successful reperfusion (OR:0.20; P< 0.001)
and symptomatic intracranial hemorrhage (OR: 4.17; P< 0.001) as the best independent predictors of outcome.
Conclusion Our study showed a not negligible rate of intracranial carotid artery occlusion with patent intracranial arteries,
presenting mostly as severe stroke, with an acceptable rate of 3-month functional independence. Age, NIHSS at presentation
and successful reperfusion were the best independent predictors of outcome.
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Introduction
Recent endovascular stroke trials reported an incidence of
intracranial carotid artery occlusion (ICAO) ranging be-
tween 16% and 31% of all acute ischemic strokes [1, 2];
however, most of the reports regarding this issue did not
specify if ICAO was associated or not with middle or ante-
rior cerebral artery occlusion. In this respect a challenging
condition is represented by an infraclinoid and/or supracli-
noid ICAO associated with patent large intracranial arteries.
In the Multicenter Randomized Clinical Trial of Endovas-
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cular Treatment for Acute Ischemic Stroke in the Nether-
lands (MR CLEAN) the rate of this type of lesion was
0.4% in the intervention group and 1.1% in the control
group while in the Revascularization with Solitaire FR De-
vice versus Best Medical Therapy in Anterior Circulation
Stroke Within 8h of Symptom Onset (REVASCAT) trial
it was 0% and 1.0%, respectively [3, 4]. These data tes-
tify how underinvestigated this condition is even though
included among indications for mechanical thrombectomy
(MT) of the American Stroke Association guidelines [5].
The aim of our study was to explore baseline and procedu-
ral characteristics, outcomes and predictors of outcome in
patients with acute ischemic stroke secondary to ICAO with
patent intracranial arteries receiving MT in a large national
registry.
Material andMethods
The data that support the findings of this study are available
upon reasonable request (coordinamento@registroendo
vascolare.it). Data were retrieved from the Italian Reg-
istry of Endovascular Treatment in Acute Stroke (IRETAS)
which is a multicenter, prospective, observational internet-
based registry (Appendix in the online-only Data Supple-
ment). Patients were included in the analysis if they had
an ICAO (infraclinoid and/or supraclinoid) with or without
cervical artery occlusion but with patency of intracranial
arteries diagnosed on computed tomography (CT) angiog-
raphy and confirmed on conventional angiography through
contrast medium injection of contralateral unaffected ICA.
Demographics, baseline clinical and procedural character-
istics were assessed. The following main outcomes were
evaluated:
 3-month functional independence evaluated by modified
Rankin scale (mRS) and defined as a mRS ≤2;
 mortality;
 successful reperfusion evaluated by means of thrombol-
ysis in cerebral infarction (TICI) and defined as a TICI
≥2b;
 symptomatic intracranial hemorrhage (sICH) defined, ac-
cording to the European Cooperative Acute Stroke Study
criteria [6], as a parenchymal hematoma associated with
an increase of at least 4 points in the National Institute of
Health Stroke Scale (NIHSS) or death.
Need for ethical approval or patient consent for partici-
pation in the IRETAS varied among participating hospitals.
Ethical approval and patient consent were obtained where
required.
Statistical Analysis
Univariate analysis was performed to compare baseline and
procedural characteristics and outcomes between 3-month
good (mRS ≤2) and poor functional (mRS >2) outcome
groups and between ICAO group and a control group of
anterior circulation occlusions treated with MT, i.e. tandem
and middle cerebral artery (MCA) occlusion.
Continuous variables are summarized as median with in-
terquartile range (IQR). Categorical variables are expressed
as percentages. To determine differences between the two
groups, a Student’s t-test or Mann-Whitney U-test for con-
tinuous variables was performed whereas comparison of
frequencies was performed with the χ2-test.
Based on significant variables in univariate analysis
(p≤ 0.10), multivariable ordinal logistic regression analysis
was carried out to identify predictors of 3-month func-
tional outcome adjusting for different variables in different
models.
Results
Between 2015 and 2018 a total of 5783 patients with
anterior circulation large vessel stroke were identified. A
3-month follow-up was available in 4940 (85.4%) (Ta-
ble I in the online-only Data Supplement). An ICAO was
diagnosed in 387/4940 (7.8%) patients (Table II in the
online-only Data Supplement). Median age was 74 years
(range 63–81 years) and median baseline NIHSS was 18
(range 14–21). An ICAO presented more often as severe
stroke with an NIHSS >15 in 67% of the cases, whereas
minor (NIHSS ≤6) to moderate (NIHSS 7–15) stroke oc-
curred in 4% and 28%, respectively (Table 1). Intravenous
thrombolysis was performed in 175 (46%) patients of the
total sample, functional independence was achieved in 130
(34%), successful reperfusion in 289 (75%) and sICH in
33 (9%) patients of the whole sample, whereas mortality
occurred in 111 (29%) patients (Table 1). When comparing
patients with good outcome and those with poor outcome
at 3-month follow-up, functional independence was associ-
ated to lower age (70 years vs. 76 years), lower NIHSS at
presentation (16 vs. 19), lower rate of hypertension and dia-
betes (51% vs. 65%; 8% vs. 19%), higher rate of successful
reperfusion (95% vs. 65%) and lower rate of sICH (3% vs.
13%) as shown in Table 1. Table 2 shows a comparison
of baseline characteristics and outcomes after MT between
ICAO with patent intracranial arteries and M1 segment of
MCA. The ICAO presented with higher NIHSS (18 vs. 17),
were more frequently treated with the patient under general
anesthesia (57% vs. 39%), showed lower rate of successful
reperfusion (TICI ≥2b, 75% vs. 82%) and of 3-month func-
tional independence (mRS 0–2, 34% vs. 50%) and higher
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Age, years, median (IQR) 74(63–81) 70(59–78) 76(67–83) <0.001
Age >80 years, n (%) 111(29) 19(15) 92(36) <0.001
Male, n (%) 169(44) 57(44) 112(44) 0.960
Baseline NIHSS, median (IQR)
missing 16
18(14–21) 16(12–19) 19(15–22) <0.001
Baseline NIHSS ≤6, n (%) 16(4) 8(6) 8(3) <0.001
Baseline NIHSS 7–15, n (%) 105(28) 51(39) 54(22)
Baseline NIHSS >15, n (%) 250(67) 70(54) 180(74)
Baseline ASPECTS, mean (SD)
(49 missing)
8.9(1.6) 9.1 (1.3) 8.8 (1.7) 0.131
Vascular risk factors, n (%) missing 90
Atrial fibrillation 109(37) 33(32) 76(39) 0.261
Diabetes 46(15) 8(8) 38(19) 0.008
Hypertension 178(60) 52(51) 126(65) 0.023
Coronary artery disease 38(13) 12(12) 26(13) 0.701
Valvular heart disease 31(8) 7(5) 24(9) 0.176
Congestive heart failure 20(7) 8(8) 12(6) 0.581
Smoking habit 43(14) 20(20) 23(12) 0.069
Hypercholesterolemia 58(19) 21(21) 37(19) 0.739
IV thrombolysis, n (%) missing 4 175(46) 65(50) 110(43) 0.225
Time to groin puncture, median (IQR) missing 28 245(184–314) 235(175–315) 250(190–313) 0.528
Time to end procedure, median (IQR) missing 41 325(260–400) 310(240–389) 330(270–410) 0.081
Anesthesia, n (%) missing 78
General anesthesia 176(57) 57(55) 119(58) 0.146
Sedation 90(29) 27(26) 63(31)
None 43(14) 20(19) 23(11)
Thrombectomy technique, n (%) missing 85
Stentriever 60(20) 23(21) 37(19) 0.887
Thromboaspiration 144(48) 50(46) 94(48)
Combined 98(32) 35(32) 63(32)
Successful reperfusion, n (%)
missing 2
289(75) 124(95) 165(65) <0.001
Symptomatic intracranial hemorrhage, n (%) missing
39
33(9) 3(3) 30(13) 0.002
Subarachnoid hemorrhage, n (%) 6(2) 1(1) 5(2) 0.376
Functional independence at 3 months, n (%) 130(34) – – –
Mortality at 3 months, n (%) 111(29) – – –
ASPECTS Alberta Stroke Program Early CT Score, NIHSS National Institute of Health Stroke Scale
mortality (29% vs. 17%) without a difference in sICH.
Table 3 shows a comparison of baseline characteristics and
outcomes after MT between ICAO with patent intracranial
arteries and tandem lesions (defined as the combination of
an extracranial carotid artery disease and intracranial large
vessel occlusion). The rate of extracranial internal carotid
artery stenting in this registry was 35%. Data for peripro-
cedural and postprocedural antithrombotic treatment were
not available. The ICAO were older (74 vs. 68 years), had
a lower rate of prestroke functional independence (92%
vs. 99%), presented with higher NIHSS (18 vs. 16), had
higher rate of atrial fibrillation (37% vs. 12%), were treated
more frequently with the patient under general anesthesia
(57% vs. 44%), showed lower rate of 3-month functional
independence (34% vs. 52%) and higher mortality (29%
vs. 14%) without difference in successful reperfusion and
sICH. Multivariable ordinal logistic regression analysis is
shown in Table 4. Two predictive models were constructed:
one without (model A) and one with (model B) variables
of the posttreatment phase, such as TICI and sICH. In
the first one, age (OR: 1.03; 95% confidence interval, CI
1.01–1.04), baseline NIHSS (OR: 1.07; 95% CI 1.03–1.12)
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Table 2 Comparison of baseline characteristics, procedural characteristics and outcomes after mechanical thrombectomy between intracranial








Age, years median (IQR) 75(65–81) 74 (63–81) 75(65–81) 0.174
Age >80 years, n (%) 906(31) 111 (29) 795(31) 0.327
Male, n (%) 1269(43) 169 (44) 1100(43) 0.834
Prestroke mRS 0–2, n (%) 2430(95) 328 (92) 2102(96) 0.007
Baseline NIHSS, median (IQR) missing 74 17(13–20) 18 (14–21) 17(12–20) <0.001
Baseline NIHSS ≤6, n (%) 167(6) 16 (4) 151(6) 0.011
Baseline NIHSS 7–15, n (%) 969(34) 105 (28) 864(35)
Baseline NIHSS >15, n (%) 1729(60) 250 (68) 1479(59)
Baseline ASPECTS, mean (SD)
(348 missing)
8.9 (1.4) 8.9 (1.6) 9.0 (1.4) 0.667
Vascular risk factors, n (%) missing 409
Atrial fibrillation 922(36) 109(37) 813(36) 0.922
Diabetes 405(16) 46(16) 359(16) 0.795
Hypertension 1636(65) 178(60) 1458(65) 0.069
Coronary artery disease 287(11) 38(13) 248(11) 0.401
Valvular heart disease 196(7) 31(8) 165(7) 0.256
Congestive heart failure 192(8) 20(7) 172(8) 0.554
Smoking habit 387(15) 43(15) 344(15) 0.677
Hypercholesterolemia 620(25) 58(20) 562(25) 0.034
IV thrombolysis, n (%) missing 26 1541(53) 175(46) 1366(54) 0.003
Time to groin puncture, median (IQR) missing 181 240(180–310) 245(184–314) 240(180–310) 0.236
Time to end procedure, median (IQR) missing 247 305(240–377) 325(260–400) 300(237–375) <0.001
Anesthesia, n (%) missing 548
General anesthesia 980(41) 176(57) 804(39) <0.001
Sedation 810(34) 90(29) 720(35) –
None 601(25) 43(14) 558(27) –
Thrombectomy technique, n (%) missing 562
Stentriever 615(26) 60(20) 555(27) <0.001
Thromboaspiration 1202(50) 144(48) 1058(51) –
Combined 560(24) 98(32) 462(22) –
Successful reperfusion, n (%) missing 22 2367(81) 289(75) 2978(82) 0.001
Symptomatic intracranial hemorrhage, n (%) missing
266
212(8) 33(9) 179(8) 0.251
Subarachnoid hemorrhage, n (%) missing 4 93(3) 6(2) 87(3) 0.051
Functional independence at 3 months, n (%) 1407(48) 130(34) 1277(50) <0.001
Mortality at 3 months, n (%) 546(19) 111(29) 435(17) <0.001
ASPECTS Alberta Stroke Program Early CT Score, mRS modified Rankin Scale, NIHSS National Institute of Health Stroke Scale
and diabetes (OR: 2.60; 95% CI 1.40–4.84) resulted as the
best independent predictors of poor outcome. In model B
these variables remained significant independent predictors
but less than TICI 2b-3 (OR: 0.20; 95% CI 0.11–0.36) and
sICH (OR: 4.17; 95% CI 1.88–9.24).
Discussion
ICAO with patent intracranial arteries remains an under-
investigated lesion among anterior circulation ischemic
strokes, despite it not being an unusual condition. In this
analysis of the IRETAS we found a not negligible rate
of 7.8% of cases. This rate appears to be almost eightfold
higher than that reported in the MR CLEAN trial [3]. A rea-
son for that could be the sample size of our study, which
was almost tenfold larger, and the less strict selection cri-
teria of our population compared with the abovementioned
randomized clinical trial. In any case, this is a finding
from a real-world setting analysis and it should give an
idea of the chance of facing such a condition. Another
relevant finding was that ICAO with patent intracranial
K
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Table 3 Comparison of baseline characteristics, procedural characteristics and outcomes between intracranial carotid artery occlusion with patent








Age, years median (IQR) 71(60–79) 74(63–81) 68(58–76) <0.001
Age >80 years, n (%) 149(22) 111(29) 38(13) <0.001
Male, n (%) 375(54) 169(44) 206(68) <0.001
Pre-stroke mRS 0–2 n (%) missing 53 607(95) 328(92) 279(99) <0.001
Baseline NIHSS, median (IQR) missing 16 17(13–21) 18(14–21) 16(11–20) <0.001
Baseline NIHSS ≤6, n (%) 58(9) 16(4) 42(14) <0.001
Baseline NIHSS 7–15, n (%) 204(30) 105(28) 99(33)
Baseline NIHSS >15, n (%) 408(61) 250(68) 158(53)
Baseline ASPECTS, mean (SD)
(83 missing)
9.0 (1.5) 8.9 (1.6) 9.0 (1.4) 0.519
Vascular risk factors, n (%) missing 143
Atrial fibrillation 140(26) 109(37) 31(12) <0.001
Diabetes 89(16) 46(16) 43(17) 0.618
Hypertension 323(59) 178(60) 145(58) 0.570
Coronary artery disease 56(10) 38(13) 18(7) 0.029
Valvular heart disease 40(6) 31(8) 9(3) 0.005
Congestive heart failure 30(6) 20(7) 10(4) 0.155
Smoking habit 118(22) 43(15) 75(30) <0.001
Hypercholesterolemia 129(24) 58(20) 71(28) 0.017
IV thrombolysis, n (%) missing 7 343(50) 175(46) 168(56) 0.010
Time to groin puncture, median (IQR) missing 26 240(179–315) 245(184–314) 230(166–317) 0.172
Time to end procedure, median (IQR) missing 39 325(269–405) 325(260–400) 330(264–410) 0.771
Anesthesia, n (%) missing 135
General anesthesia 284(51) 176(57) 108(44) 0.003
Sedation 175(31) 90(29) 85(34) –
None 98(18) 43(14) 55(22) –
Thrombectomy technique, n (%) missing 157
Stentriever 111(21) 60(20) 51(22) 0.377
Thromboaspiration 241(45) 144(48) 97(42) –
Combined 183(34) 98(32) 85(37) –
Successful reperfusion, n (%) missing 5 531(77) 289(75) 242(80) 0.116
Symptomatic intracranial hemorrhage, n (%) missing
160
53(8) 33(9) 20(7) 0.271
Subarachnoid hemorrhage, n (%) missing 68 21(3) 6(2) 15(5) 0.010
Functional independence at 3 months, n (%) 288(42) 130(34) 158(52) <0.001
Mortality at 3 months, n (%) 153(22) 111(29) 42(14) <0.001
ASPECTS Alberta Stroke Program Early CT Score, mRS modified Rankin Scale, NIHSS National Institute of Health Stroke Scale
arteries presented with minor symptoms only in 4% of
the cases, with a moderate to severe stroke in most of the
cases (95%). This is of relevance when considering that
facing such a condition, especially when associated with
fluctuating or minor symptoms as a consequence of patent
primary collateral pathway (i.e. anterior and/or posterior
communicating artery), could make therapeutic decisions
more challenging. A conflict may arise between the will
to act and the fear of doing harm; however, the rate of
moderate to severe stroke and NIHSS at presentation in the
overall population in this study testifies that minor stroke
is an almost rare condition. Unfortunately, the paucity of
minor strokes secondary to ICAO in our sample did not
enable further analysis of this interesting subgroup to be
performed.
To the best of our knowledge only one study has specifi-
cally investigated carotid artery occlusion [7]. It was aimed
to explore safety and efficacy outcomes in different occlu-
sion sites where carotid was involved, such as T (carotid
plus origin of middle and/or anterior cerebral artery) or
tandem lesions. In a further analysis of the same study the
authors compared ICAO (80 patients) with a group of tan-
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Table 4 Multivariable ordinal logistic regression analysis best predictors of poor outcome
Model A Model B
P OR (95% CI) P OR (95% CI)
Age (years) 0.006 1.03 (1.01–1.04) 0.016 1.02 (1.01–1.04)
Baseline NIHSS <0.001 1.07 (1.03–1.12) <0.001 1.08 (1.04–1.12)
Diabetes 0.002 2.60 (1.40–4.84) 0.011 2.37 (1.21–4.63)
Hypertension 0.933 0.98 (0.60–1.61) 0.777 1.08 (0.64–1.81)
Smoking habit 0.157 0.64 (0.34–1.19) 0.034 0.50 (0.27–0.95)
Time to end procedure (h) 0.072 1.06 (0.99–1.13) 0.191 1.05 (0.98–1.12)
Successful reperfusion – – <0.001 0.20 (0.11–0.36)
Symptomatic intracranial hemorrhage – – <0.001 4.17 (1.88–9.24)
NIHSS National Institute of Health Stroke Scale
dem lesions and found higher intrahospital mortality, lower
rate of 3-month functional independence and of successful
reperfusion in the first group [7]. The same results were
found in our study except for successful reperfusion which
was similar in the two groups.
It remains unclear why severity is higher and outcome
worse in ICAO compared to tandem occlusion stroke de-
spite patent intracranial arteries and activation of primary
collateral pathways in ICAO. A possible explanation is that
endovascular treatment of ICAO itself might be less safe
due to distal embolization in unaffected territories; how-
ever, heterogeneity of treatment in such a multicenter reg-
istry does not allow definite conclusions on this point to
be made and further investigation is needed. This compari-
son, together with the one proposed with MCA occlusion in
our analysis, confirms the severity of ICAO with patent in-
tracranial arteries in the wide spectrum of lesions treatable
by MT.
As age and NIHSS at admission are confirmed as two of
the best independent predictors of outcome, our study sug-
gests that ICAO should be treated without hesitation with
MT like any other scenario. After all, in those cases where
minor to moderate symptoms are supposed to be the result
of primary and secondary collateral pathways, it is fore-
seeable that hemodynamic compensation will reduce with
time [8]. In light of this, our advice for treating ICAO with
MT, even in the presence of patent intracranial circulation,
is further supported by the finding that successful reperfu-
sion is confirmed to be a strong independent predictor of
outcome in this type of occlusion too. In this perspective it
seems useful to evaluate the anatomy of the circle of Willis
and global intracranial collateral flow on CT angiography
in order to get an idea, especially in cases without clear
indication to MT such as minor stroke, of the ability of
hemodynamic compensation over time [9].
Limitations
Our study has several limitations. First, it is a retrospective
analysis. Second, data have been analyzed from a registry
and therefore affected by heterogeneity of treatment proto-
cols of different participating centers. Third, the number of
missing data most of all regarding available 3-month fol-
low-up and vascular risk factors might have influenced the
final outcome; however, baseline characteristics of patients
excluded because of missing follow-up did not differ from
those of included patients, except for prevalence of valvular
heart disease (Supplemental Table I). Fourth, no analysis of
outcome measures related to collaterals or occlusion loca-
tion in relation to posterior communicating artery or ante-
rior choroidal artery or any other collateral pathway could
be done because of missing data in more than half of the pa-
tients. Fifth, data concerning underlying stroke mechanisms
were missing in more than half of the patients and therefore
could not be analyzed; however, vascular risk factor analy-
sis showed a similar rate of atrial fibrillation between ICAO
and M1 occlusion (Table 2), whereas this rate, together with
the one of valvular heart disease, was significantly higher
in ICAO compared to tandem occlusion (Table 3) suggest-
ing a possible cardioembolic mechanism underlying ICAO.
Furthermore, the lack of an imaging core laboratory in our
registry may have led to incorrect classification of arterial
lesions and overestimation of our findings. The general low
agreement in the definition of tandem lesion may have in-
crease this bias. Therefore, generalizability of our results
should be made with caution. Despite this, our internet-
based registry consists of a highly itemized data sheet for
each phase of treatment which guarantees detailed informa-
tion. Finally, to the best of our knowledge, this is the largest
set of data on this specific issue referring to a real-world
scenario.
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Summary
In conclusion, our results suggest that in a real-world set-
ting ICAO with patency of intracranial circulation is a far
from rare event, in most of the cases showing as moderate
to severe stroke, with an acceptable rate of 3-month favor-
able outcome. Age, severity at presentation and successful
reperfusion are the best independent predictors of outcome.
Future studies should better address the rarer subgroup of
minor ICAO-related stroke.
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